2016
HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China
Chen X, Zou X, He J, Zheng J, Chiarella J, Kozal MJ. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China. PLOS ONE 2016, 11: e0149215. PMID: 26895182, PMCID: PMC4760947, DOI: 10.1371/journal.pone.0149215.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsVirologic failureDetection of DRMsPrevalence of DRMsSanger sequencingHIV drug resistance mutationsResistance mutationsART-experienced patientsART-experienced subjectsTreatment-experienced subjectsMedian viral loadNNRTI resistance mutationsStandard genotypingART adherenceViral loadAE subtypeMutation prevalenceDeep sequencingFailure subjectsExperienced subjectsResistant variantsOnly variablePatientsPrevalenceSubtypes
2014
Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, China
Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, Blake LA, Turenchalk G, Kozal MJ. Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, China. PLOS ONE 2014, 9: e98740. PMID: 24896087, PMCID: PMC4045886, DOI: 10.1371/journal.pone.0098740.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-HIV AgentsCD4 Lymphocyte CountDrug Resistance, ViralFemaleGenotypeHigh-Throughput Nucleotide SequencingHIV InfectionsHIV-1HumansMaleMiddle AgedMutationPrevalenceViral LoadYoung AdultConceptsART-naïve subjectsFirst-line antiretroviral therapyLine Antiretroviral TherapyPI TDRsDrug resistance mutationsNNRTI TDRAntiretroviral therapyPI mutationsPI/r useTransmitted Drug Resistance MutationsResistance mutationsAntiretroviral-naïve subjectsAdvanced chronic diseaseHigh-level resistanceAdvanced diseaseNNRTI mutationsNevirapine resistanceNRTI resistanceHIV variantsTime of testingChronic diseasesAE subtypeTreatment responseSubtype AER use
2012
Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing
Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E, Kozal M. Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing. PLOS ONE 2012, 7: e30118. PMID: 22355307, PMCID: PMC3280244, DOI: 10.1371/journal.pone.0030118.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsAtazanavir SulfateDrug Resistance, ViralGenotypeHigh-Throughput Nucleotide SequencingHIV InfectionsHIV Protease InhibitorsHIV-1HumansLopinavirMutationOligopeptidesPyridinesRitonavirViral LoadConceptsPI/rDrug-resistant mutationsVirologic failureUltra-deep sequencingR regimenLow-level resistant variantsMajor PI resistance mutationsPI/r regimenResistant variantsARV-naïve subjectsPI-resistant variantsHIV-positive patientsAtazanavir/ritonavirLopinavir/ritonavirM184V/ILow-level variantsPI resistance mutationsMinority of casesTenofovir/RegimenStanford HIVdbResistance mutationsPhenotypic resistanceResistant mutationsStandard genotyping
2011
Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant Levels
Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M. Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant Levels. Antiviral Therapy 2011, 16: 925-929. PMID: 21900725, DOI: 10.3851/imp1851.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug Resistance, ViralGenetic VariationGenotypeHigh-Throughput Nucleotide SequencingHIV InfectionsHIV Reverse TranscriptaseHIV-1HumansMutationViral LoadConceptsTreatment-naive individualsDifferent HIV-1 subtypesARV-naive subjectsHIV-1 subtypesAntiretroviral exposureViral loadSubtype CUltra-deep sequencingReverse Transcriptase Mutation K65RRitonavir-boosted protease inhibitorHIV-1 subtype CResistant variantsAntiretroviral drug exposurePlasma viral loadTreatment-naive subjectsLow-level variantsPre-therapy levelsHIV-1 variantsDrug resistance mutationsMutation K65RVirological failureSubtype BDrug exposureMutational loadHigh mutation load